Distilled Bio
← Samples

Marcus's clinical briefing

Marcus is a clinical and translational development professional focused on rare disease gene therapy, especially AAV programs moving through early clinical testing. He tracks dose escalation data, durability, immunogenicity, liver toxicity, vector shedding, redosing strategies, and pediatric trial design to understand both efficacy and safety risk.

Marcus

Selected topics

  • AAV gene therapy clinical development
  • Rare disease trial design, endpoints, and natural history studies
  • Safety signals, immunogenicity, liver toxicity, and vector shedding
  • Biomarker validation, patient selection, and translational strategy
  • Regulatory feedback, real-world evidence, and scientific conference readouts

Updated August 12, 2026 at 6:50 AM

Create yours
FDA clearance for Graviton BioScience’s GV101, an Xtalks webinar on NGS from difficult clinical samples, and fresh questions around MoonLake’s data disclosure.